Find the most appropriate genomic study for each indication:

SOLID TUMORS

Description:
 
Study of sensitivity and resistance to targeted chemotherapy Suitable for all types of tumors It increases treatment options for cancer
Indications:

  • Refractory patients
  • Aggressive tumors
  • Optimization of small tumoral sample
  • Negative biomarkers
  • Rare tumors
  • Tumors of unknown origin
Test:

OncoDEEP (NGS 313 genes + P.Plus*)

OncoSTRAT&GO (NGS 313 genes + P.Plus* + monitoring in liquid biopsy 40 genes)

*P.Plus: IHQ, FISH, PCR, Metilation...setected by type tumor

Turnaround Time: 7-10 days

Turaround time: 10 days

Access to the platform OncoSHARE

UNRESECTABLE SOLID TUMORS

Description:
 
Non-invasive tumor sequencing test that allows to identify genomic alterations and match them to treatment options
 
Suitable for all types of tumors
 
Avoid unnecessary biopsies
 
Monitores and detects early progression and treatment failure
Indications:

  • Unresectable tumors
  • Stage III/IV
  • Limited or old tumor sample
  • Suspected relapse
  • Refractory patients
  • Aggressive, rare and unknown origin tumors
Test:

OncoSELECT™ (NGS>100 specific mutations of lung cancer, breast ER+/HER2+ or colon))

Turnaround Time: 7 days (OncoSELECT)

NEWLY DIAGNOSED BREAST CANCER

Description:
 
Identification of intrinsic subtype (Luminal A, Luminal B, HER2-Enriched and Basal-like)

10-Year likelihood and Risk of Distant Recurrence

Benefit of adjuvant chemotherapy

Benefit of hormonal therapy after 5 years    
Indications:

  • Stage I or II and HR+ and node-negative (N0)
  • Stage II or IIIA, HR+ and between 1-3, 4 or more node-positive
Test:

Prosigna® - PAM50 (NanoString) Analysis of the expression of 50 genes

Turnaround Time: 10 days

INHERITED CANCER RISK

Description:
 
Risk analysis for hereditary cancer prevention
Indications:

  • Family history of cancer
  • Early diagnosis age
  • Patient with multiple cancers
Test:

BioSeq Hereditario (NGS 106 genes)

Turnaround Time: 6-8 weeks

MONITORING

Description:
 
Non invasive test in blood to monitor and early detect the progression and the therapeutical failure
 
Indications:

  • Monitoring of mutations in liquid biopsy after a previous study in solid or liquid biopsy
Test:

OncoTRACE (NGS 40 genes + 15 personalised variants)

Turnaround Time: 10 days

Are you looking for another type of genetic test?

Contact us at +34 961829 423 and we will inform you of the more than 140 tests placed at your disposal.